What are the different stages of Multiple Myeloma? REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS)
IMWG Revised International Staging System Multiple Myeloma REVISED - INTERNATIONAL STAGING SYSTEM is based on blood work results and...
Dec 1, 2021
313
Virtual Meeting: 2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021
2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021 Chicago, IL 2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021 Learn more:...
Dec 1, 2021
256
clonoSEQ: Adaptive Biotechnologies - What is Minimal residual disease (MRD)?
What is Minimal residual disease (MRD)? MRD (Minimal Residual Disease) is a small number of malignant plasma cells that remain in the...
Dec 1, 2021
286
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With...
Dec 1, 2021
306
Virtual Conference: Lymphoma, Leukemia & Myeloma Congress - October 19-23, 2021 New York
Virtual Conference: Lymphoma, Leukemia & Myeloma Congress October 19-23, 2021 New York Learn more: https://lymphomaandmyeloma.oncnet.com/
Dec 1, 2021
132
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...
Dec 1, 2021
147
26th Annual International Congress on Hematologic Malignancies®: Leukemias, Lymphomas, and Myeloma
The 26th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma Eden Roc Miami Beach 4525...
Dec 1, 2021
129
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...
Dec 1, 2021
3,023
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...
Aug 20, 2021
178
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...
Aug 20, 2021
373
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With...
Aug 12, 2021
151
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)
Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...
Aug 10, 2021
152
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...
Aug 7, 2021
230
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...
Aug 7, 2021
864
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in...
Aug 7, 2021
60
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...
Aug 6, 2021
238
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...
Aug 6, 2021
771
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) NCT04960579: Phase 1:...
Aug 5, 2021
128
18th International Myeloma Workshop : September 8 - 11, 2021 - Vienna, Austria
18th International Myeloma Workshop September 8 - 11, 2021 - Vienna, Austria The International Myeloma Workshop is the defining meeting...
Aug 1, 2021
355
2021 SOHO Annual meeting : Ninth annual meeting Society of Hematologic Oncology Sep. 8-11, 2021.
The Society of Hematologic Oncology's Ninth Annual Meeting is scheduled as a virtual event on September 8-11, 2021. The focus of the...
Aug 1, 2021
184
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma...
Jun 28, 2021
200
THE MMRF - Multiple Myeloma Immunotherapy
THE MMRF - Multiple Myeloma Immunotherapy THE MMRF - Multiple Myeloma Immunotherapy Click here to read Learn more: Multiple Myeloma...
Jun 27, 2021
98
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)
PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...
Jun 26, 2021
185
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research Manufacturing CAR T Cells to...
Jun 26, 2021
240